Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.
Tiley
C
C
Leukaemia Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Powles
R
R
Teo
C P
CP
Treleaven
J
J
Findlay
M
M
Hewetson
M
M
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology; D006086:Graft vs Host Disease / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods*; D008558:Melphalan / Q000627:therapeutic use; D051379:Mice; D010865:Pilot Projects; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D015375:Receptors, Interleukin-2; D003520:Cyclophosphamide; D008558:Melphalan